Allergan

Allergan is developing a treatment for the redness of rosacea based on Oxymetazoline, currently called AGN-199201. Allergan is also known to rosacea sufferers because they make Restasis and Aczone.

Recent Rosacea Blog Posts

What is Rhofade?

In the coming months you will see more and more references to Rhofade. When a new rosacea treatment launches everyone wants to know what is it ? Asking this question makes sense as we normally only find out the name of a product right at the end of the development process. What we now know […]

Continue Reading

Rhofade approval expected early 2017

One little pearl from the Allergan investor presentation is that the company is expecting Rhofade to be approved by the FDA in early 2017. Allergan Plc (AGN) Brenton L. Saunders on Q2 2016 Results – Earnings Call Transcript Aug. 8, 2016 2:03 PM ET About: Allergan plc (AGN) William J. Meury – Chief Commercial Officer […]

Continue Reading

Allergan – Oxymetazoline has no rebound

In a document prepared for Allergan’s November 4, 2015 R&D Day presentation, Allergan is highlighting the development of its soon to be approved oxymetazoline 1% cream for rosacea. The slides relating to Oxymetazoline show the features of this product, along with other products in development, that Allergan wants to promote to investors. In the presentation […]

Continue Reading

Oxymetazoline 1% Cream for 1H 2017

Allergan today have confirmed that a new drug application for their 1% oxymetazoline hcl cream has been formally lodged with the FDA. The prediction from Allergan is that the approval will come in the first half of 2017. This is the first confirmation that Allergan has settled on a 1% formulation of oxymetazoline hydrochloride, having […]

Continue Reading

Allergan’s Oxymetazoline gentler than Mirvaso

Two small updates on the progress of topical oxymetazoline towards being available as another treatment for the redness of rosacea. The update tells us firstly that Allergan’s Oxymetazoline based product is in indeed in the final stages of approval, having completed Phase 3 trials and been submitted to the FDA for final approval. Secondly the […]

Continue Reading

 

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.